EMBECTA CORP. Operating Income
EMBECTA CORP. (EMBC) reported Operating Income of $48.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-07
- EMBECTA CORP. operating income (loss) for the quarter ending 2026-06-30 was $48.70M, a 48.19% decline year-over-year.
- EMBECTA CORP. operating income (loss) for the quarter ending 2026-03-31 was $35.00M, a 44.36% decline year-over-year.
- EMBECTA CORP. operating income (loss) for the quarter ending 2025-12-31 was $83.30M, a 190.24% increase year-over-year.
- EMBECTA CORP. operating income (loss) for the quarter ending 2025-09-30 was $56.50M, a 115.65% increase year-over-year.
- EMBECTA CORP. operating income (loss) for fiscal 2025 was $242.10M, a 45.14% increase from fiscal 2024.
- EMBECTA CORP. operating income (loss) for fiscal 2024 was $166.80M, a 24.70% decline from fiscal 2023.
- EMBECTA CORP. operating income (loss) for fiscal 2023 was $221.50M, a 28.46% decline from fiscal 2022.
- EMBECTA CORP. operating income (loss) for fiscal 2022 was $309.60M, a 37.07% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.70M 10-Q · filed 2026-08-07 | $83.70M derived: sum of 2 quarters · filed 2026-08-07 | $167.00M 10-Q · filed 2026-08-07 | $223.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $35.00M 10-Q · filed 2026-05-05 | $118.30M 10-Q · filed 2026-05-05 | $174.80M derived: sum of 3 quarters · filed 2026-05-05 | $268.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $83.30M 10-Q · filed 2026-02-05 | $139.80M derived: sum of 2 quarters · filed 2026-02-05 | $233.80M derived: sum of 3 quarters · filed 2026-08-07 | $296.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $56.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $150.50M derived: sum of 2 quarters · filed 2026-08-07 | $213.40M derived: sum of 3 quarters · filed 2026-08-07 | $242.10M 10-K · filed 2025-11-25 |
| 2025-06-30 | $94.00M 10-Q · filed 2026-08-07 | $156.90M derived: sum of 2 quarters · filed 2026-08-07 | $185.60M 10-Q · filed 2026-08-07 | $211.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $62.90M 10-Q · filed 2026-05-05 | $91.60M 10-Q · filed 2026-05-05 | $117.80M derived: sum of 3 quarters · filed 2026-05-05 | $173.70M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $28.70M 10-Q · filed 2026-02-05 | $54.90M derived: sum of 2 quarters · filed 2026-02-05 | $110.80M derived: sum of 3 quarters · filed 2026-02-05 | $150.00M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $26.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $82.10M derived: sum of 2 quarters · filed 2025-11-25 | $121.30M derived: sum of 3 quarters · filed 2025-11-25 | $166.80M 10-K · filed 2025-11-25 |
| 2024-06-30 | $55.90M 10-Q · filed 2025-08-08 | $95.10M derived: sum of 2 quarters · filed 2025-08-08 | $140.60M 10-Q · filed 2025-08-08 | $166.40M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $39.20M 10-Q · filed 2025-05-09 | $84.70M 10-Q · filed 2025-05-09 | $110.50M derived: sum of 3 quarters · filed 2025-11-25 | $161.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $45.50M 10-Q · filed 2025-02-06 | $71.30M derived: sum of 2 quarters · filed 2025-11-25 | $122.60M derived: sum of 3 quarters · filed 2025-11-25 | $178.20M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $25.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $77.10M derived: sum of 2 quarters · filed 2025-11-25 | $132.70M derived: sum of 3 quarters · filed 2025-11-25 | $221.50M 10-K · filed 2025-11-25 |
| 2023-06-30 | $51.30M 10-Q · filed 2024-08-09 | $106.90M derived: sum of 2 quarters · filed 2024-08-09 | $195.70M 10-Q · filed 2024-08-09 | $192.70M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $55.60M 10-Q · filed 2024-05-09 | $144.40M 10-Q · filed 2024-05-09 | $141.40M derived: sum of 3 quarters · filed 2024-12-11 | $238.50M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $88.80M 10-Q · filed 2024-02-09 | $85.80M derived: sum of 2 quarters · filed 2024-12-11 | $182.90M derived: sum of 3 quarters · filed 2024-12-11 | $281.80M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | -$3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $94.10M derived: sum of 2 quarters · filed 2024-12-11 | $193.00M derived: sum of 3 quarters · filed 2024-12-11 | $309.60M 10-K · filed 2024-12-11 |
| 2022-06-30 | $97.10M 10-Q · filed 2023-08-08 | $196.00M derived: sum of 2 quarters · filed 2023-08-08 | $312.60M 10-Q · filed 2023-08-08 | $429.80M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $98.90M 10-Q · filed 2023-05-12 | $215.50M 10-Q · filed 2023-05-12 | $332.70M derived: sum of 3 quarters · filed 2023-11-29 | $457.00M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $116.60M 10-Q · filed 2023-02-14 | $233.80M derived: sum of 2 quarters · filed 2023-11-29 | $358.10M derived: sum of 3 quarters · filed 2023-11-29 | $484.50M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $117.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $241.50M derived: sum of 2 quarters · filed 2023-11-29 | $367.90M derived: sum of 3 quarters · filed 2023-11-29 | $492.00M 10-K · filed 2023-11-29 |
| 2021-06-30 | $124.30M 10-Q · filed 2022-08-15 | $250.70M derived: sum of 2 quarters · filed 2022-08-15 | $374.80M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $126.40M 10-Q · filed 2022-05-13 | $250.50M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $124.10M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $486.50M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |